Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in Precision Cancer Care for Community Practitioners: A Focus on NTRK- and RET-Altered Malignancies
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: June 10, 2022 Expiration: June 9, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Lilly
Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
person default
Saad A. Khan, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Order appropriate screening to detect NTRK and RET gene fusions
  • Describe the clinical research data supporting the use of TRK inhibition in NTRK fusion–positive and RET fusion–positive patients across all solid tumors
  • Summarize ongoing research regarding the efficacy and safety of selective RET inhibitors in patients with RET fusion–positive mutations across various tumor types
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK and RET inhibitor therapy

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consultant/advisor/speaker fees from 14ner/Elevation Oncology, AbbVie, Amgen, Applied Pharmaceutical Science ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharm, EMD Serono, EPG Health, Entos, Exelixis, Harborside, Helsinn, Hengrui, Ignyta/Genentech/Roche, Janssen, Liberum, Loxo/Bayer/Lilly, mBrace, Medendi, Merus, Monopteros, MORE Health, Nexus, Novartis, Nuvalent, Ology, Pfizer, Prelude, Remedica, Repare RX, RV More, Takeda/Ariad/Millennium, TouchIME, TP Therapeutics, Treeline Bio, Tyra Biosciences, and Verastem and funds for research support (paid to institution) from Exelixis, GlaxoSmithKline, PharmaMar, Pfizer, Taiho, and Teva.
Thomas Stinchcombe, MD

Professor of Medicine
Department of Medicine
Duke University School of Medicine
Member, Duke Cancer Institute
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Janssen Oncology, Lilly, Medtronic, Novartis, Pfizer, Puma Biotechnology, Regeneron, Turning Point Therapeutics, Sanofi/Aventis, and Takeda and funds for research support paid to his institution from Advaxis, AstraZeneca, Genentech/Roche, Mirati, Regeneron, and Takeda.

Faculty

Saad A. Khan, MD

Assistant Professor of Medicine (Oncology)
Leader
, Endocrine Cancers Research Group
Stanford Cancer Institute
Stanford University
Stanford, California

Saad A. Khan, MD, has disclosed that he has received consultant/advisor/speaker fees from Eisai and Foundation Medicine.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Nathan Beach, PhD

Editorial Contributor

Nathan Beach, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kelly Brandt, PharmD
Kelly Brandt, PharmD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has disclosed that she has received speaker fees from AstraZeneca. Bristol-Myers Squibb, DSI, Gilead, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Target Audience

This program is intended for community medical oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with NTRK- and RET-altered malignancies.

Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with NTRK- and RET-altered malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-153-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 10, 2022, through June 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Advances in Precision Cancer Care for Community Practitioners: A Focus on NTRK- and RET-Altered Malignancies
  • CME
  • CE

Loading...
Watch this on-demand webcast of a live CCO webinar to gain expert insight on managing NTRK- and RET-altered malignancies, including optimal methods for detecting gene fusions.
Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
person default
Saad A. Khan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: June 10, 2022 Expiration: June 9, 2023

Related Content

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings